Related Experiment Videos
Immune intervention against virus-associated human cancers
1CRC Institute for Cancer Studies, University of Birmingham, Edgbaston, U.K.
Summary
Epstein-Barr virus (EBV) vaccines targeting envelope glycoproteins or EBNA3-derived CTL epitopes show promise. CTL-based immunotherapy also demonstrates potential for reversing viral-associated cancers.
Area of Science:
- Oncology
- Virology
- Immunology
- Vaccinology
Background:
- Several viruses, including Epstein-Barr virus (EBV), are carcinogenic, contributing to cancer development through complex pathogenesis.
- EBV-associated tumors are a focus for immune intervention strategies, aiming to prevent infection or eliminate virus-positive cancer cells.
Purpose of the Study:
- To review and discuss potential immune interventions for EBV-associated cancers.
- To highlight the development of envelope glycoprotein-based vaccines and CTL epitope-based vaccines.
- To explore the application of CTL-based immunotherapy for viral-associated malignancies.
Main Methods:
- Investigated EBV envelope glycoprotein (gp340)-based vaccines, targeting neutralizing antibody responses.
- Examined cytotoxic T-lymphocyte (CTL) epitope-based vaccines using EBNA3-derived synthetic peptides.
- Assessed CTL-based immunotherapy involving the administration of activated T-cells.
Main Results:
- A gp340-based vaccine demonstrated protection against EBV-associated lymphoproliferative disease in an animal model, with Phase I clinical trials commencing.
- Clinical trials are evaluating the efficacy of EBNA3-derived CTL epitope-based vaccines.
- Activated T-cell administration has shown success in reversing lymphoproliferative disease post-bone marrow transplantation.
Conclusions:
- Vaccines targeting EBV's gp340 or EBNA3-derived CTL epitopes represent promising avenues for cancer prevention and treatment.
- CTL-based immunotherapy offers a potential therapeutic strategy for EBV-associated cancers and other malignancies.